

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETELY KNOWN	
			Application Number	To Be Assigned 10/541270
			Filing Date	
			First Named Inventor	Monaci, et al.
			Group Art Unit	1646
			Examiner Name	
Sheet 2	of 3	Attorney Docket Number	ITR0043YP	

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/CK/	E	Bargmann, et al., "The neu oncogene encodes an epidermal growth factor receptor-related protein", Nature, Vol. 319, 16 January 1986, pp. 226-230.
	F	Chartier, et al., "Efficient Generation of Recombinant Adenovirus Vectors by Homologous Recombination in Escherichia coli", J. of Virology, Vol. 70, No. 7, July 1996, pp. 4805-4810.
	G	Cheever, et al., "Immunity to Oncogenic Proteins", Immunological Reviews, No. 145, 1995, pp. 33-59.
	H	Coussens, et al., "Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene", Science, Vol. 230, 6 December 1985, pp. 1132-1139.
	I	Disis, et al., "Oncogenic proteins as tumor antigens", Current Opinion in Immunology, Vol. 8, 1996, pp. 637-642.
	J	Disis, et al., "HER-2/neu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer", Advances in Cancer Research, Vol. 71, pp. 343-371, 1997.
	K	Disis, et al., "Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide-Based Vaccines", J. of Clin. Oncol., Vol. 20, No. 11, pp. 2624-2632, 2002.
	L	Disis, et al., "Cancer Vaccines Targeting the Her2/neu Oncogenic Protein", Seminars in Oncology, Vol. 28, No. 6, Suppl.18, pp. 12-20, December 2001.
	M	Foy, et al., "Vaccination with HER-2/neu DNA or protein subunits protects against growth of a HER-2/neu-expressing murine tumor", Vaccine, Vol. 19, pp. 2598-2606, 2001.
	N	King, et al., "Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinoma", Science, Vol. 229, pp. 974-976, 1985.
	O	Lohrisch, et al., "An Overview of HER2", Seminars in Oncology, Vol. 28, No. 6, Suppl 19, December 2001, pp. 3-11.
	P	Montgomery, et al., "Heterologous and Homologous Protection Against Influenza A by DNA Vaccination: Optimization of DNA Vectors", DNA and Cell Biology, Vol. 13, No. 9, 777-792, 1993.
	Q	Press, et al., "Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues", Oncogene, Vol. 5, pp. 953-962, 1990.
↓	R	Shih, et al., "Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts", Nature, Vol. 290, 19 March 1981, pp. 261-264.
/CK/	S	Shiver, et al., "Cytotoxic T Lymphocyte and Helper T Cell Responses following HIV Polynucleotide Vaccination", Annals New York Academy of Sciences, Vol. 772, pp. 198-208, 1996.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETELY KNOWN

Application Number

To Be Assigned

107541270

Filing Date**First Named Inventor**

Monaci, et al.

Group Art Unit

1646

Examiner Name

Attorney Docket Number

ITR0043YP

NON PATENT LITERATURE DOCUMENTS

**Examiner
Initials***Cite
No.

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

/CK/

T

Slamon, et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer", *Science*, Vol. 244, pp. 707-712, May 12, 1989.

/CK/

U

Slichenmyer, et al., "Anticancer Therapy Targeting the ErbB Family of Receptor Tyrosine Kinases", *Seminars in Oncology*, Vol. 28, No. 5, Suppl. 16, October 2001, p. 67-79.

/CK/

V

Yarden, Y. "Biology of HER2 and Its Importance in Breast Cancer", *Oncology*, Vol. 61 (Suppl 2), 2001, pp. 1-13.

**Examiner
Signature**

/Claire Kaufman/

Date Considered

05/14/2007

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

INFORMATION DISCLOSED
 OIPE
 BY APPLI
 DEC 20 2005
 PATENT & TRADEMARK OFFICE
 many sheets as needed

(use as many sheets as necessary)

Sheet

1

of

2

Application Number

10/541,270

Filing Date

~~July 1, 2005~~ 01/30/2006

First Named Inventor

Monaci, et al.

Group Art Unit

1646

Examiner Name

Kaufman

Attorney Docket Number

ITR0043YP

[illegible][illegible]

**Examiner
Signature**

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
				Application Number	10/541,270
				Filing Date	July 1, 2006
				First Named Inventor	Monaci, et al.
				Group Art Unit	1646
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	ITR0043YP

[illegible]

Examiner Signature	/Claire Kaufman/	Date Considered	05/14/2007
-----------------------	------------------	--------------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form * IDS Form* (IDS Folder), Merck & Co., Inc., -7/12/2005